notification_important

MHRA alerts & recalls

Review medicine recalls, record your assessment and keep track of follow-up actions.

All alerts

Read the alert. Keep a record of your response.

Create a free PharmData login to receive notifications. An active Starter or Pro subscription enables your pharmacy team to record assessments and follow-up actions.

Create a free account Sign in

2019-10-16 09:24:29 · Revision 1

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

Aventis Pharma Limited t/a Sanofi has informed the MHRA that a change to the Patient Information Leaflet concerning possible side effects for Rifadin (rifampicin) 150mg Capsules has not been implemented by the required …

Read full MHRA notice ↗

Source: Medicines and Healthcare products Regulatory Agency (MHRA). Read the full notice, including its required actions and deadlines, before recording your response.

PharmData The OG Pharmacy Data Tool

Data sources & attribution

Data is provided by the NHSBSA, HSC Business Services Organisation, NHS Wales & Information Services Division of NHS National Services Scotland. Contains public sector information licensed under the Open Government Licence v3.0, including Office for National Statistics, ISP (National MIS Files), Information Services Data Warehouse NHSBSA Copyright 2026. All data is unverified and PharmData Ltd takes no responsibility for any inaccuracies.

© 2026 PharmData Ltd